Immix Biopharma (IMMX) Set to Release Quarterly Earnings on Friday

Immix Biopharma (NASDAQ:IMMX – Get Free Report) will likely be announcing its Q3 2026 resultson Friday, November 6th. Analysts expect Immix Biopharma to post earnings of ($0.18) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Immix Biopharma (NASDAQ:IMMX – Get Free Report) last issued its earnings results on Friday, August 7th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). On average, analysts expect Immix Biopharma to post ($0.76) EPS for the current fiscal year and ($0.86) EPS for the next fiscal year.

Immix Biopharma Trading Down 1.8%

Shares of IMMX stock opened at $7.98 on Friday. Immix Biopharma has a 1-year low of $2.85 and a 1-year high of $15.10. The company has a market capitalization of $570.89 million, a price-to-earnings ratio of -9.07 and a beta of 0.24. The stock’s fifty day simple moving average is $11.13 and its 200-day simple moving average is $9.42.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Citigroup reissued a “market outperform” rating on shares of Immix Biopharma in a research note on Wednesday, September 30th. HC Wainwright raised their price objective on Immix Biopharma from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research note on Thursday, October 15th. Morgan Stanley reiterated an “overweight” rating on shares of Immix Biopharma in a report on Tuesday, October 20th. Finally, Needham & Company LLC upped their target price on Immix Biopharma from $21.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, September 29th. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Immix Biopharma has a consensus rating of “Moderate Buy” and an average target price of $23.86.

View Our Latest Research Report on Immix Biopharma

About Immix Biopharma

(Get Free Report)

Immix Biopharma, Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with difficult-to-treat cancers and other serious diseases. The company’s research and development activities are centered on engineered immune-cell treatments intended to target malignant cells.

Its lead product candidate is NXC-201, an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy designed to target B-cell maturation antigen (BCMA). NXC-201 is being evaluated in clinical studies for relapsed or refractory multiple myeloma and relapsed or refractory AL amyloidosis, a rare blood disorder in which abnormal plasma cells produce misfolded proteins.

Immix Biopharma was founded in 2012 and is headquartered in Los Angeles, California.

Featured Stories

Earnings History for Immix Biopharma (NASDAQ:IMMX)

Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.